Psilocybin rapidly and sustainably reduces depressive and anxiety symptoms in patients with major depressive disorder and those with life-threatening cancer. MDMA decreases depressive symptoms in patients with life-threatening cancer, autism spectrum disorder, and post-traumatic stress disorder, but its effect on generalized anxiety symptoms is negligible or negative, while it reduces social anxiety. Ayahuasca reduces depressive symptoms in treatment-resistant major depressive and personality disorders. LSD decreases anxiety in life-threatening cancer. Adverse effects include elevated blood pressure, headaches, panic attacks, and for MDMA, feeling cold.
Psilocybin produced a rapid and sustained reduction in depressive and anxiety symptoms in patients with major depressive disorder and in those with life-threatening cancer. MDMA reduced depressive symptoms in patients with life-threatening cancer, autism spectrum disorder, and post-traumatic stress disorder, and reduced social anxiety, but its effect on anxiety symptoms overall was negligible or negative. Ayahuasca reduced depressive symptoms in individuals with treatment-resistant major depressive and personality disorders. LSD reduced anxiety symptoms in individuals with life-threatening cancer. Adverse effects included elevated blood pressure, headaches, and panic attacks for psilocybin and MDMA, plus feeling cold for MDMA.